Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
Go back to Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057| Temoris Resources, Inc. (NASDAQ: MORF) | Delayed: 27.53 +0.02 (0.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.51 | 52 Week High | $0.14 | |||
| Open | $27.27 | 52 Week Low | $0.14 | |||
| Day High | $28.12 | P/E | N/A | |||
| Day Low | $27.26 | EPS | $0.00 | |||
| Volume | 32,016 | |||||
